The nation of Zimbabwe has declined a significant American health deal valued at $367m (£272m) spanning five years due to Washington's demand for confidential biological samples.
This rejection became public after a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
A government representative later clarified that the US was demanding access to health data for scientific study and profit but was unwilling to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued negotiations to reach a deal acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This development follows a comparable situation in Kenya, where a high court blocked a related deal with the US following concerns were filed about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to boost openness and accountability.
As per statements, Sixteen nations in Africa have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our population should a new disease outbreak emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its push of bilateral deals were undermining structures previously set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with potential global health emergencies.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to continued discussions with our US partners on how subsequent co-operation might be arranged in a way that honours the sovereignty and interests of each country."
Medical Community Response
A leading public health body stated it understood the official position, but suggested that talks should continue considering a large portion of the country's HIV programmes were funded by external financing.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
The situation emphasises the continuing tensions between accepting vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.